Influenza Human Viral Challenge Studies

Influenza Human Viral Challenge Studies

Contract Research

Information

hVIVO is the global leader in conducting human viral challenge studies also recently referred to as Controlled Human Infection Models or CHIM. We specialize in respiratory viruses and conduct challenge studies for influenza, Respiratory Syncytial Virus(RSV), and Human Rhinovirus (HRV) hVIVO has conducted 26 influenza human viral challenge studies and inoculated over 1300 subjects with our various influenza strains. hVIVO is the unsurpassed global leader in conducting this type of research since 2001. The current hVIVO H3N2 challenge strain exhibits stronger performance for infection rate and measurable disease than any other influenza challenge strain currently available.
hVIVO​hVIVO plc (“hVIVO”), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

Log in